+7.2%
VNQ vs GSK
+47.2%
-40.0%
-34.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.7% | 0.0% | +0.7% | +0.7% |
| 7D | -1.3% | -3.5% | +2.3% | -0.4% |
| 30D | -2.6% | -3.4% | +0.9% | -1.8% |
| 3M | -2.0% | -8.1% | +6.1% | -0.1% |
| 6M | +4.3% | -11.1% | +15.5% | +7.0% |
| YTD | +9.2% | +0.7% | +8.5% | +8.5% |
| 1Y | +5.6% | +20.1% | -14.5% | +0.1% |
| 3Y | +30.8% | +46.1% | -15.3% | +15.8% |
| All | +7.2% | +47.2% | -40.0% | -8.7% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling